As a co-founder of Enterprise Therapeutics, Henry is Head of Biology. He gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. Whilst with Novartis, he worked as an in vitro/in vivo pharmacologist with a specialisation in airway epithelial cell-based drug targets. During this time, he played a central role in establishing the CF discovery portfolio and was most recently Director and Head of the Lung Repair & Regeneration Group in the Respiratory Disease Area. He has led many drug discovery programs from target identification through to early clinical studies as well as authoring over 50 peer reviewed papers, patents, and book chapters.